HCM
TBPH icon

Highbridge Capital Management’s Theravance Biopharma TBPH Stock Holding History

Highbridge Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-325,000
Closed -$3.65M – 477
2022
Q4 		$3.65M Sell
325,000
-13,000
-4% -$137K 0.1% 197
2022
Q3 		$3.43M Buy
+338,000
New +$3.17M 0.05% 293

Other funds holding TBPH

WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Highbridge Capital Management's TBPH Position: Q1 2024 in Review

Highbridge Capital Management sold out of Theravance Biopharma (TBPH) in Q1 2024, closing a stake of 166,234 shares — an estimated $1.87M sold.

Highbridge Capital Management first reported a position in TBPH in Q4 2014 and held it in 9 quarters. The position peaked at $8.53M in Q2 2021. 121 funds tracked by Wall St. Rank hold TBPH as of Q1 2024.

  • Highbridge Capital Management reported no remaining Theravance Biopharma position as of Q1 2024 after selling out during the quarter.
  • Highbridge Capital Management sold 166,234 Theravance Biopharma shares in Q1 2024, an estimated $1.87M.
  • Highbridge Capital Management first reported a position in Theravance Biopharma in Q4 2014 and held it in 9 quarters.
  • Highbridge Capital Management's Theravance Biopharma position peaked at $8.53M in Q2 2021.
  • 121 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2024.

Based on Highbridge Capital Management's 13F filing for Q1 2024, filed 10 May 2024.